{"id":34196,"date":"2021-07-27T09:00:00","date_gmt":"2021-07-27T07:00:00","guid":{"rendered":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/"},"modified":"2023-09-20T11:11:08","modified_gmt":"2023-09-20T09:11:08","slug":"ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway","status":"publish","type":"press_release","link":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/","title":{"rendered":"Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway"},"content":{"rendered":"<ul>\n<li style=\"list-style-type:none;margin-bottom:3px\">\n<ul>\n<li style=\"margin-bottom:3px\">Investigational BKX-001 is an oral small-molecule activator of BAX, developed as a potential treatment for leukemia, lymphoma and solid tumors1<\/li>\n<li style=\"margin-bottom:3px\">Ipsen obtains an exclusive license to research, develop, manufacture and commercialize novel therapeutics targeted to the BCL-2 associated protein (BAX), an effector of apoptosis<\/li>\n<\/ul>\n<ul>\n<li style=\"margin-bottom:3px\">Ipsen and BAKX Therapeutics Inc. will be jointly responsible for research and development activities and will jointly share in the profits from commercialization<\/li>\n<\/ul>\n<p><b>Paris (France), 27 July 2021 \u2013\u00a0<\/b>Ipsen (Euronext: IPN; ADR: IPSEY) and BAKX Therapeutics Inc. have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture and commercialize BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.<br \/>\nApoptosis is the naturally occurring process of programmed cell death. Deregulated apoptosis can lead to uncontrolled cell division and the development of a tumor.2\u00a0The apoptosis cell-signaling pathway has been proven to be a target for cancer therapy with the development and approval of BCL-2 inhibitors for the treatment of certain hematological malignancies.3\u00a0BAX is a novel target in this pathway that is downstream of all anti-apoptotic proteins like BCL-2, BCL-XL, MCL-1 etc.4\u00a0Direct activation of BAX has several possible outcomes as an investigational cancer therapy, potentially addressing multiple tumor types and the resistance encountered while targeting only the antiapoptotic BCL-2 family proteins. BAX activation by small-molecule agonists have been shown to promote apoptosis in leukemia-cell lines and human samples, while sparing healthy cells in vitro and suppress human acute myeloid leukemia xenografts and increased host survival without toxicity in vivo.5<br \/>\nDr. Howard Mayer, Executive Vice President and Head of Research and Development, Ipsen, said \u201cAs part of our strategy, we continue to strengthen our pipeline and deliver exciting external-innovation opportunities. We are, therefore, delighted to partner with the expert team at BAKX Therapeutics to move BKX-001 into further preclinical development, with the goal of achieving a development candidate that can be evaluated for the potential treatment of hematological malignancies and solid tumors. Importantly, this collaboration also reflects the shared values across our two organizations and, as a result, we will be building a strong cross-company team to advance this innovation for people living with these forms of cancer, and their healthcare teams.\u201d<br \/>\nSree Kant, Founder and CEO of BAKX Therapeutics Inc. said \u201cWe are excited to partner with Ipsen on investigational BKX-001. This program is the result of pioneering work on the BAX protein driven by our scientific co-founders Loren D Walensky and Evripidis Gavathiotis. This partnership brings together Ipsen\u2019s excellent clinical development and commercial capabilities with our industry-leading knowledge of the BAX protein and our unique computational platform. This is a collaboration of very distinct complementary capabilities that can together drive important treatment options in cancer therapy for patients, faster.\u201d<br \/>\nUnder the agreement, Ipsen will pay BAKX Therapeutics Inc. $14.5m upon closing, comprising an equity investment and an upfront payment, followed by up to $837.5m in milestone payments. The companies would also share equally costs and profits.<\/li>\n<\/ul>\n<ol>\n<li style=\"margin-bottom:3px\">BAKX Therapeutics. The apoptosis company. Pipeline.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRmcVsDHLcuF0FQXHCUgv5f2L6vduv4w7TU_GdnaeFPqQy-zTmGLkGUfSAkW0KyN3SekPH4K-nUP9iZYVbhDm_RVM8fS4Y9pB7i9SP7H7OnyW\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/bakxtx.com\/pipeline\/<\/b><\/a>\u00a0(last accessed July 2021).<\/li>\n<li style=\"margin-bottom:3px\">National Human Genome Research Institute.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRv4JkAb4wzmwnYJCCozXVhD4SidyLCGG7NgFYBf8Gj-c9SSyyVCV215XJeYgbXfYTPvmEwkvy8k6ByCUAH8uuuphK3_M_iJIBRvqvVv5y3VPL0RP7HfnboV8n8CSwQZ1y39PIWf1i5_pCw9ln4RpvLc=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.genome.gov\/genetics-glossary\/apoptosis<\/b><\/a>\u00a0(last accessed July 2021).<\/li>\n<li style=\"margin-bottom:3px\">Venclyxto SmPC. European Medicines Agency. Available here:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRqkoT5QUKZpAteeUQlVGX-VISSRF-vpsByQ3P-nHKYk7PJYj0Bv-l3l5FFkMg8ktnlCmRrFXobyfq14sJVLEtsogZKzCQa_kJ1BjRM7aXuLFYZiJhgHwLk0O7SxHVYYkgcfbmQ5GtLThDxy8Ny2wY08ubh17_F-mqaypRQe_8U9L\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/venclyxto<\/b><\/a><\/li>\n<li style=\"margin-bottom:3px\">A.R.D. Delbridge and A. Strasser Cell Death Differ., 22 (2015), pp. 1071-1080. Available here:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRgFCAMJ3dpfyE8HN0sXl8fMJNyeBU4bINOfxb8hGSBPf8g_JSOudM705ENTjjr_GKnwF8QD-G6w1p2fo96qmxSphqkqzhacUbsTeMGz920UhMkA6dHF78MUgAx3Obh192A==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.nature.com\/articles\/cdd201550<\/b><\/a>.<\/li>\n<li style=\"margin-bottom:3px\">D.E. Reyna, T.P. Garner, A. Lopez, F. Kopp, G.S. Choudhary, A. Sridharan, S.R. Narayanagari, K. Mitchell, B. Dong, B.A. Bartholdy et al. Cancer Cell, 32 (2017), pp. 490-505. Available here:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YtCwbt32kE6tAtLcUn2qRnon2VwOZEJ163R805iK65Sy3H182NlNe5i-DmFjTvlHyZTeOGzkJshcRolMofdugW09OylCy7epxeBuh2Ik_Ja-dVMrHoBXwwE8NdGN8dd9EM_yZCxJYZwjSs1A2vYKt_iIqjNU44aMl0fSsXri5xZLPER5vNefjvkGoI3bCjUlxi_eqlZKav0_0OTrx4bPFw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><b>https:\/\/www.cell.com\/cancer-cell\/fulltext\/S1535-6108(17)30364-1<\/b><\/a><\/li>\n<\/ol>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Attachment<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=yDd4meqRVVXyabtcZ4G593sXffkIYibQorlAQ6-PYJGg6jPXtku4ndDCSystSu1gPUYSfP8__98IjLPMdleMfQJ98JnzBpKRG3EWkbrDG1SAPscmYJiwIt8LIFAj1-cvy8VKTvRH0rws3Ia3agKWcikpABt-wDtYY5I0tMA2mJkngW9DAyaMPsWWUDQpH-xj1Dfsaid7jnQ7k0sGz0DwJA==\" title=\"Ipsen-BAKX-collaboration-27-July-2021\" rel=\"nofollow noopener\">Ipsen-BAKX-collaboration-27-July-2021<\/a><\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[1769],"tags":[],"class_list":["post-34196","press_release","type-press_release","status-publish","hentry","category-partnering-pressrelease","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway - Global<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway - Global\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-20T09:11:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/\",\"name\":\"Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway - Global\",\"isPartOf\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2021-07-27T07:00:00+00:00\",\"dateModified\":\"2023-09-20T09:11:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#website\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/d3glparxwv1yl3.cloudfront.net\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway - Global","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway - Global","og_url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/","og_site_name":"Global","article_modified_time":"2023-09-20T09:11:08+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/","name":"Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway - Global","isPartOf":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#primaryimage"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2021-07-27T07:00:00+00:00","dateModified":"2023-09-20T09:11:08+00:00","breadcrumb":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/ODZiNWNmOTktODg2Ny00ODlmLWFkMjItOWUxNTBmNDQ0NzIyLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/press-releases\/ipsen-strengthens-its-pre-clinical-oncology-pipeline-with-an-exclusive-worldwide-collaboration-with-bakx-therapeutics-inc-for-bkx-001-targeting-the-apoptosis-pathway\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d3glparxwv1yl3.cloudfront.net\/"},{"@type":"ListItem","position":2,"name":"Ipsen strengthens its pre-clinical Oncology pipeline with an exclusive worldwide-collaboration with BAKX Therapeutics Inc. for BKX-001, targeting the apoptosis pathway"}]},{"@type":"WebSite","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#website","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/","name":"Global","description":"","publisher":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d3glparxwv1yl3.cloudfront.net\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#organization","name":"IPSEN","url":"https:\/\/d3glparxwv1yl3.cloudfront.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/04\/17170708\/Logo_IPSEN.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/d3glparxwv1yl3.cloudfront.net\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]}]}},"_links":{"self":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/press_release\/34196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":1,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/press_release\/34196\/revisions"}],"predecessor-version":[{"id":35207,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/press_release\/34196\/revisions\/35207"}],"wp:attachment":[{"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/media?parent=34196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/categories?post=34196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/d3glparxwv1yl3.cloudfront.net\/wp-json\/wp\/v2\/tags?post=34196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}